Kintara Therapeutics Secures $2.0M National Institutes Of Health SBIR Grant To Support Clinical Development Of REM-001
Portfolio Pulse from Benzinga Newsdesk
Kintara Therapeutics has secured a $2.0M SBIR grant from the National Institutes of Health to support the clinical development of REM-001.
June 28, 2023 | 8:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kintara Therapeutics has received a $2.0M grant from the National Institutes of Health, which will likely support the company's financial stability and progress in the development of REM-001.
The grant from the National Institutes of Health will provide Kintara Therapeutics with additional funding, which can be used to further the development of REM-001. This could potentially lead to positive outcomes for the company, including financial stability and progress in their product development, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100